Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ARS PharmaceuticalsSPRY +1.51%28 PS Ratio is 6.05 as of Aug. 13, 2026, which is 99% below its 10-year median of 538.46. GuruFocus rates SPRY with a GF Score™ of 28/100. The stock has 5 warning signs investors should review. Among 930 Biotechnology companies, ARS Pharmaceuticals ranks better than 61.94% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, ARS Pharmaceuticals's share price is $6.06.
ARS Pharmaceuticals's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was $1.00. Hence, ARS Pharmaceuticals's PS Ratio for today is 6.05.
The historical rank and industry rank for ARS Pharmaceuticals's PS Ratio or its related term are showing as below:
SPRY'
s PS Ratio Range Over the Past 10 Years
Min: 5.12 Med: 538.46 Max: 5110
Current: 6.07
During the past 6 years, ARS Pharmaceuticals's highest PS Ratio was 5110.00. The lowest was 5.12. And the median was 538.46.
SPRY's PS Ratio is ranked better than 61.94% of 930
companies
in the Biotechnology industry
Industry Median: 9.6
vs SPRY: 6.07
During the past 6 years, ARS Pharmaceuticals's highest 3-Year average Revenue per Share Growth Rate was 195.90% per year. The lowest was 145.30% per year. And the median was 170.60% per year.
ARS Pharmaceuticals (NAS:SPRY) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
ARS Pharmaceuticals PS Ratio Related Terms
ARS Pharmaceuticals PS Ratio Historical Data
* Premium members only.
The historical data trend for ARS Pharmaceuticals's PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, ARS Pharmaceuticals's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ARS Pharmaceuticals PS Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, ARS Pharmaceuticals's PS Ratio distribution charts can be found below:
* The bar in red indicates where ARS Pharmaceuticals's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
ARS Pharmaceuticals's Share Price of today is $6.06. ARS Pharmaceuticals's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $1.00.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
ARS Pharmaceuticals (SPRY) has a PS Ratio of 6.05 as of Aug. 13, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on ARS Pharmaceuticals and its competitors. This is 99% below median its historical median of 538.46. Over the past decade, ARS Pharmaceuticals' PS Ratio has ranged from 5.12 to 5,110.00. According to the industry distribution chart, ARS Pharmaceuticals ranks #354 out of 930 companies in the Biotechnology industry, placing it in the top 38.1%.
Is ARS Pharmaceuticals' PS Ratio too high?
ARS Pharmaceuticals' current PS Ratio of 6.05 is 99% below median its 10-year median of 538.46. Over the past 10 years, this metric has ranged from a low of 5.12 to a high of 5,110.00. The Biotechnology industry median PS Ratio is 9.60. ARS Pharmaceuticals' value of 6.05 is 37% below this industry median. Based on the distribution chart, ARS Pharmaceuticals ranks #354 out of 930 companies in the Biotechnology industry, which is above the industry midpoint. Overall, ARS Pharmaceuticals has a GF Score™ of 28/100, reflecting its overall financial health beyond just this single metric.
How does ARS Pharmaceuticals' PS Ratio compare to ALLO and CBIO?
According to the Biotechnology industry distribution chart, ARS Pharmaceuticals ranks #354 out of 930 companies for PS Ratio. This puts ARS Pharmaceuticals in the upper half of its industry. The industry median PS Ratio is 9.60. ARS Pharmaceuticals' value of 6.05 is 37% below this benchmark. Historically, ARS Pharmaceuticals' own PS Ratio has ranged from 5.12 to 5,110.00 over the past decade. While the company's 10-year median is 538.46 vs. the industry median of 9.60, ARS Pharmaceuticals has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Biotechnology company?
The median PS Ratio among Biotechnology companies is 9.60, based on 930 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. ARS Pharmaceuticals's current PS Ratio of 6.05 is 37% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on ARS Pharmaceuticals and its competitors. For the Biotechnology industry, the median PS Ratio is 9.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. ARS Pharmaceuticals's current PS Ratio is 6.05, which is 99% below median its own 10-year median of 538.46. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ARS Pharmaceuticals stock overvalued right now?
ARS Pharmaceuticals (SPRY) has a current PS Ratio of 6.05. The current PS Ratio is 6.05, which is 99% below median its 10-year median of 538.46 and 37% below the Biotechnology industry median of 9.60. ARS Pharmaceuticals' overall GF Score™ is 28/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For ARS Pharmaceuticals (SPRY), the current PS Ratio is 6.05 as of Aug. 13, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
ARS Pharmaceuticals Inc is a biopharmaceutical company focused on the commercialization and development of neffy (currently identified in the European Union (EU) and United Kingdom (U.K.) by the trade name EURneffy and in China) for needle-free intranasal delivery of epinephrine for emergency treatment of Type I allergic reactions, including anaphylaxis. Neffy is a proprietary composition of epinephrine with an absorption enhancer called Intravail, which allows Neffy to safely provide intranasal delivery of epinephrine at a low dose within the exposures of approved injectable products across a range of dosing conditions.
28GF Score
Get the complete analysis for SPRY
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SPRY has been successfully added to your 
